Multitarget Molecular Docking Using Curcuma longa Phytocompounds for Polycystic Ovary Syndrome Treatment

Year : 2024 | Volume : 02 | Issue : 01 | Page : 15 28
    By

    Basamma D.B.,

  1. Junior Scientific Officer, Department of Moleculr Pathology Laboratory, Triesta Science, A Unit of HCG Hospital, Bangalore, Karnataka, India

Abstract

Objective: The primary goal of this research is to understand and describe specific aspects of molecular interaction, it includes studying various aspects such as binding affinity, binding mode, and stability of the ligand-protein complex. Molecular docking is a computational technique used to predict the preferred orientation of one molecule to a second when bound together to form a stable complex. In this study, molecular docking will be employed to stimulate and analyze the interaction between the ligand and the target protein. Identifying the phytocompounds for the treatment of Polycystic ovary syndrome involves exploring the plant-derived compounds with potential therapeutic effects on the symptoms and underlying mechanisms of the condition. Methods: In this study, an in silico study to develop the best phytocompounds to treat polycystic ovary syndrome (PCOS). IMPPAT database was used to retrieve the phytocompounds from Curcuma longa. The molecules selected underwent drug-likeness screening on SwissADME, and final screening was conducted using PyRx software, revealing the binding affinity between the ligands and the 1h59 target protein. The examination of 3D interactions was carried out using BIOVIA. Results: The potential lead molecules are Cinnamyl cinnamate, ar-Turmerone, and alpha-curcumene from Curcuma longa were identified to resist the insulin which helps to treat polycystic ovarian syndrome. Conclusion: All three compounds, namely cinnamyl cinnamate, ar-Turmerone, and alpha-curcumene, comply with Lipinski’s parameters, indicating their suitability for treating PCOS by regulating insulin levels. These lead molecules show prominent results in polycystic ovarian syndrome.

Keywords: Curcuma longa, molecular docking, ADME analysis, phytocompounds, insulin-like growth factor1, Lipinski rule of 5

[This article belongs to International Journal of Molecular Biotechnological Research ]

How to cite this article:
Basamma D.B.. Multitarget Molecular Docking Using Curcuma longa Phytocompounds for Polycystic Ovary Syndrome Treatment. International Journal of Molecular Biotechnological Research. 2024; 02(01):15-28.
How to cite this URL:
Basamma D.B.. Multitarget Molecular Docking Using Curcuma longa Phytocompounds for Polycystic Ovary Syndrome Treatment. International Journal of Molecular Biotechnological Research. 2024; 02(01):15-28. Available from: https://journals.stmjournals.com/ijmbr/article=2024/view=170387


Browse Figures

References

1. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37:467–520. DOI: 10.1210/er.2015-1104, PubMed: 27459230.
2. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health. 2011;3:25–35. DOI: 10.2147/IJWH.S11304, PubMed: 21339935.
3. Galluzzo A, Amato MC, Giordano C. Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis. 2008;18:511–8. DOI: 10.1016/j.numecd.2008.05.004, PubMed: 18657405.
4. Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, et al. Polycystic ovary syndrome, insulin resistance, and obesity: Navigating the pathophysiologic labyrinth. Int J Reprod Med. 2014;2014:719050. DOI: 10.1155/2014/719050, PubMed: 25763405.
5. Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, challenges, and guiding treatment. J Clin Endocrinol Metab. 2021;106:e1071–83. DOI: 10.1210/clinem/dgaa839, PubMed: 33211867.
6. Azziz R. Polycystic ovary syndrome, insulin resistance, and molecular defects of insulin signaling. J Clin Endocrinol Metab. 2002;87:4085–7. DOI: 10.1210/jc.2002-021131, PubMed: 12213851.
7. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774–800. DOI: 10.1210/edrv.18.6.0318, PubMed: 9408743.
8. Papalou O, Livadas S, Karachalios A, Tolia N, Kokkoris P, Tripolitakis K, et al. White blood cells levels and PCOS: Direct and indirect relationship with obesity and insulin resistance, but not with hyperandogenemia. Hormones. 2015;14:91–100. DOI: 10.14310/horm.2002.1563, PubMed: 25553762.
9. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006;12:324–32. DOI: 10.1016/j.molmed.2006.05.006, PubMed: 16769248.
10. Tosi F, Bonora E, Moghetti P. Insulin resistance in a large cohort of women with polycystic ovary syndrome: A comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum Reprod. 2017;32:2515–21. DOI: 10.1093/humrep/dex308, PubMed: 29040529.
11. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Adv Clin Exp Med. 2017;26:359–67. DOI: 10.17219/acem/59380, PubMed: 28791858.
12. Zesławski W, Beisel HG, Kamionka M, Kalus W, Engh RA, Huber R, et al. The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5. EMBO J. 2001;20(14):3638–44. DOI: 10.1093/emboj/20.14.3638, PubMed: 11447105; PMCID: PMC125553.
13. EMBL’s European Bioinformatics Institute. (2023). PROCHECK and PROCHECK-NMR. PROCHECK home page. [online] Ebi.ac.uk. Available from: https://www.ebi.ac.uk/thornton-srv/software/PROCHECK/.
14. Zesławski W, Beisel HG, Kamionka M, Kalus W, Engh RA, Huber R, et al. The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5. EMBO J. 2001;20:3638–44. DOI: 10.1093/emboj/20.14.3638, PubMed: 11447105.
15. PubChem. NLM. NIH. (2024). PubChem. [online] National Library of Medicine. National Institutes of Health. Available from: https://pubchem.ncbi.nlm.nih.gov/
16. Areejit Samal. (2022). IMPPAT: Indian Medicinal Plants, Phytochemistry And Therapeutics. [online] IMPPAT. Available from: https://cb.imsc.res.in/imppat/
17. Swiss Institute of Bioinformatics. (2024). SwissADME. [online] Molecular Modeling Group, Swiss Institute of Bioinformatics. Available from: http://www.swissadme.ch/
18. Dassault Systèmes (2020). Free Download: BIOVIA Discovery Studio Visualizer. [online] Dassault Systèmes. Available from: https://discover.3ds.com/discovery-studio-visualizer-download
19. SourceForge. (2024). Welcome to the PyRx Website. Virtual Screening Tool. [online] Available from: https://pyrx.sourceforge.io/
20. Mastorakos G, Lambrinoudaki I, Creatsas G. Polycystic ovary syndrome in adolescents: Current and future treatment options. Paediatr Drugs. 2006;8:311–8. DOI: 10.2165/00148581-200608050-00004, PubMed: 17037948.
21. Laskowski RA, MacArthur MW, Thornton JM. PROCHECK: Validation of protein-structure coordinates. In: International Tables for Crystallography. Chester, England: International Union of Crystallography; 2012. p. 684–7.
22. Teede HJ, Hutchison SK, Zoungas S. The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol Metab. 2007;18:273–9. DOI: 10.1016/j.tem.2007.08.001, PubMed: 17698366.
23. Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril. 2003;80:255–8. DOI: 10.1016/s0015-0282(03)00734-9, PubMed: 12909480.
24. Al Khalifah RA, Flórez ID, Dennis B, et al. The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: A systematic review and network meta-analysis protocol. Syst Rev. 2015;4:125. DOI: 10.1186/s13643-015-0105-4.
25. Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertil Steril. 2012;97:18–22. DOI: 10.1016/j.fertnstert.2011.11.036, PubMed: 22192137.
26. Homburg R. The management of infertility associated with polycystic ovary syndrome. Reprod Biol Endocrinol. 2003;1:109. DOI: 10.1186/1477-7827-1-109, PubMed: 14617367.
27. Ramezani Tehrani F, Amiri M. Polycystic ovary syndrome in adolescents: Challenges in diagnosis and treatment. Int J Endocrinol Metab. 2019;17(3):e91554. DOI: 10.5812/ijem.91554.
28. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): Arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999;84:1897–9. DOI: 10.1210/jcem.84.6.5803, PubMed: 10372683.
29. Balkrishna A, Rana M, Mishra S, Srivastava D, Bhardwaj R, Singh S, et al. Incredible combination of lifestyle modification and herbal remedies for polycystic ovarian syndrome management. Evid Based Complement Alternat Med: eCAM. 2023;2023:3705508. DOI: 10.1155/2023/3705508, PubMed: 37383339.
30. Jin P, Xie Y. Treatment strategies for women with polycystic ovary syndrome. Gynecol Endocrinol. 2018;34:272–7. DOI: 10.1080/09513590.2017.1395841, PubMed: 29084464.
31. Traub ML. Assessing and treating insulin resistance in women with polycystic ovarian syndrome. World J Diabetes. 2011;2:33–40. DOI: 10.4239/wjd.v2.i3.33, PubMed: 21537458.
32. Ebrahimi-Mamaghani M, Saghafi-Asl M, Pirouzpanah S, Asghari-Jafarabadi M. Effects of raw red onion consumption on metabolic features in overweight or obese women with polycystic ovary syndrome: A randomized controlled clinical trial. J Obstet Gynaecol Res. 2014;40:1067–76. DOI: 10.1111/jog.12311, PubMed: 24612081.
33. Naeimi SA, Hajimehdipoor H, Saber S. Comparing the effect of Nigella sativa oil soft gel and placebo on oligomenorrhea, amenorrhea and laboratory characteristics in patients with polycystic ovarian syndrome, a randomized clinical trial. Res J Pharmacogn. 2020;7:49–59.
34. Chavez GN, Jaworsky K, Basu A. The effects of plant-derived phytochemical compounds and phytochemical-rich diets on females with polycystic ovarian syndrome: A scoping review of clinical trials. Int J Environ Res Public Health. 2023;20. DOI: 10.3390/ijerph20156534, PubMed: 37569074.

Regular Issue Subscription Original Research
Volume 02
Issue 01
Received 23/01/2024
Accepted 13/02/2024
Published 29/02/2024
Publication Time 37 Days
316

Login


My IP

PlumX Metrics